v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY AND REDEEMABLE NONCONTROLLING INTERESTS (UNAUDITED) - USD ($)
shares in Thousands, $ in Thousands
Total
Total Charles River Laboratories, Inc. Equity
Common Stock
Additional Paid-In Capital
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Treasury Stock
Noncontrolling Interest
Beginning balance at Dec. 31, 2022 $ 42,427              
Increase (Decrease) in Temporary Equity                
Net income 322              
Other comprehensive (loss), net of tax 186              
Ending balance at Apr. 01, 2023 42,935              
Beginning balance (in shares) at Dec. 31, 2022     50,944          
Beginning balance at Dec. 31, 2022 2,981,078 $ 2,976,293 $ 509 $ 1,804,940 $ 1,432,901 $ (262,057) $ 0 $ 4,785
Beginning balance (in shares) at Dec. 31, 2022             0  
Increase (Decrease) in Stockholders' Equity                
Net income 103,632 103,131     103,131     501
Other comprehensive (loss), net of tax 22,933 22,933       22,933    
Adjustment of redeemable noncontrolling interests to redemption value 0              
Issuance of stock under employee compensation plans (in shares)     316          
Issuance of stock under employee compensation plans 11,792 11,792 $ 3 11,789        
Purchase of treasury shares (in shares)             78  
Purchase of treasury shares (19,012) (19,012)         $ (19,012)  
Stock-based compensation 13,460 13,460   13,460        
Ending balance (in shares) at Apr. 01, 2023     51,260          
Ending balance at Apr. 01, 2023 3,113,883 3,108,597 $ 512 1,830,189 1,536,032 (239,124) $ (19,012) 5,286
Ending balance (in shares) at Apr. 01, 2023             78  
Beginning balance at Dec. 30, 2023 56,722              
Increase (Decrease) in Temporary Equity                
Net income 1,201              
Other comprehensive (loss), net of tax (2,763)              
Adjustment of redeemable noncontrolling interests to redemption value 4,807              
Dividends to noncontrolling interests (2,192)              
Ending balance at Mar. 30, 2024 $ 57,775              
Beginning balance (in shares) at Dec. 30, 2023 51,338   51,338          
Beginning balance at Dec. 30, 2023 $ 3,602,276 3,596,882 $ 513 1,905,578 1,887,218 (196,427) $ 0 5,394
Beginning balance (in shares) at Dec. 30, 2023 0           0  
Increase (Decrease) in Stockholders' Equity                
Net income $ 73,281 72,960     72,960     321
Other comprehensive (loss), net of tax (53,492) (53,492)       (53,492)    
Adjustment of redeemable noncontrolling interests to redemption value (4,807) (4,807)   (4,406) (401)      
Dividends to noncontrolling interests 0              
Issuance of stock under employee compensation plans (in shares)     214          
Issuance of stock under employee compensation plans 21,505 21,505 $ 2 21,503        
Purchase of treasury shares (in shares)             42  
Purchase of treasury shares (9,351) (9,351)         $ (9,351)  
Stock-based compensation $ 16,738 16,738   16,738        
Ending balance (in shares) at Mar. 30, 2024 51,510   51,552          
Ending balance at Mar. 30, 2024 $ 3,646,150 $ 3,640,435 $ 515 $ 1,939,413 $ 1,959,777 $ (249,919) $ (9,351) $ 5,715
Ending balance (in shares) at Mar. 30, 2024 42           42